<DOC>
	<DOCNO>NCT01773928</DOCNO>
	<brief_summary>The purpose study determine Vero cell-derived trivalent seasonal influenza vaccine produce modified manufacturing process : 1. induces immune response comparable produce current manufacturing process 2. acceptable safety profile compare licensed trivalent seasonal influenza vaccine 3. demonstrate consistency immune response among three different lot .</brief_summary>
	<brief_title>Inactivated Split Virus Seasonal Influenza Vaccine ( Vero Cell-Derived )</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Participant 18 49 year age , inclusive , time screening ( Cohort 18 49 year age ) ; Participant 50 year age , inclusive , old time screening ( Cohort 50 year age old ) ; Participant give write informed consent prior study entry Participant generally healthy without significant medical risk condition , determine Investigator 's clinical judgment collection medical history performance physical examination ; Participant willing able comply requirement protocol ; Participant agree keep record symptom duration study ; If female capable bearing child participant negative urine pregnancy test study site , within 36 hour prior vaccination , agree employ adequate birth control measure duration study . For purpose study adequate birth control measure incorporate one follow FDA approve birth control measure duration study : Hormonal type birth control ( implant , birth control pill , patch method ) intrauterine device , OR A barrier type birth control measure ( i.e. , condom , diaphragm , cervical cap , etc. ) . Participant vaccinate seasonal trivalent influenza vaccine current season ; Participant oral temperature ≥100.4°F ( ≥38.0°C ) day vaccination study ; Participant receive live vaccine within 4 week , inactivated subunit vaccine within 2 week study entry ; Participant know history infection Human Immunodeficiency Virus ( HIV ) , Hepatitis B Virus ( HBsAgs ) Hepatitis C Virus ( HCV ) ; Participant medically diagnose suspect immune deficient condition base medical history physical examination determine Investigator ; Participant immune compromise condition disease , currently undergo form treatment undergoing form treatment within 30 day prior study entry expect influence immune response . Such treatment include , limited , systemic high dose inhale corticosteroid ( &gt; 800 μg/day beclomethasone dipropionate equivalent ) , radiation treatment immunosuppressive cytotoxic drug ( use inhale nasal steroid permit ) ; Participant know history Guillain Barré Syndrome , demyelinate disorder ( include acute demyelinate encephalomyelitis ( ADEM ) , Multiple Sclerosis ) convulsion ; Participant history severe allergic reaction anaphylaxis determined Investigator ; Participant rash , dermatologic condition tattoo may interfere injection site reaction rating determine Investigator ; Participant receive blood product ( e.g . blood transfusion immunoglobulin ) within 90 day prior study entry ; Participant donate one unit blood ( approximately 450 mL ) plasma within 30 day prior study entry ; Participant functional surgical asplenia ; Participant know suspect problem alcohol drug abuse determine Investigator ; Participant member team conduct study dependent relationship one study team member . Dependent relationship include close relative ( ie. , child , partner/spouse , sibling , parent ) well employee Investigator study site personnel conduct study ; If female , participant pregnant lactating time study enrollment ; Participant currently enrol participate another clinical study involve investigational product ( IP ) investigational device within 30 day prior study enrolment schedule participate another clinical study involve IP investigational device course study ; Participant condition opinion Investigator would interfere evaluation vaccine interpretation study result .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Active immunization influenza disease</keyword>
</DOC>